



Clinical Management and Outcomes of Lung Cancer Patients

Guest Editors:

Dr. Jason S. Agulnik

Peter Brojde Lung Cancer Centre,
Jewish General Hospital,
Montreal, QC H3T 1E2, Canada

Dr. Victor Cohen

Peter Brojde Lung Cancer Centre,
Jewish General Hospital,
Montreal, QC H3T 1E2, Canada

Deadline for manuscript
submissions:

31 December 2024

Message from the Guest Editors

Dear Colleagues,

Dr. Victor Cohen and I are guest editors for an upcoming Special Issue on Clinical Management and Outcomes of Lung Cancer Patients. Lung cancer represents the most-diagnosed malignancy and the leading cause of cancer-related mortality in the world. There have been significant breakthroughs in the treatment and management of lung cancer, which have increased survival rates among patients with all stages of lung cancer. Thanks to new and novel therapies such as targeted therapies and immunotherapy, lung cancer survival has improved in all stages of disease. Treatments are now tailored to a patient's particular type of lung cancer. These new therapeutic advancements have drastically improved patients' conditions with better prognosis and quality of life.

With this Special Issue, we aim at obtaining an overview of the latest advancements available in the clinical management and outcomes of lung cancer patients. We welcome original research articles and reviews. We look forward to receiving your contributions.

Dr. Jason S. Agulnik

Dr. Victor Cohen

Guest Editors

